Browsing Tag
ALS trial
1 post
NeuroSense Therapeutics (NASDAQ: NRSN) gets FDA nod for pivotal ALS trial: Is PrimeC nearing commercial breakthrough?
NeuroSense gains FDA clearance for Phase 3 ALS trial of PrimeC, with patient enrollment and global execution plans underway. Find out what comes next.